Skip to main content
Premium Trial:

Request an Annual Quote

Amersham Biosciences Withdraws IPO, Citing Amersham Acquisition

NEW YORK, April 24 - Amersham Biosciences, which filed for an initial public offering as APBiotech in October 2000, withdrew its offering from the SEC yesterday, citing the company's recent acquisition by Amersham. In February last year, after several delays, the company had set a price of $15-$17 per share for 18,200,000 shares of common stock and said it would use the cash for "general corporate purposes, primarily to fund our operations and to pay indebtedness."


In March Amersham said it planned to buy Pharmacia's 45 percent stake in Amersham Biosciences for £704 million, or roughly $992 million.


 At the time of its filing, Amersham listed as its competitors: PE Biosystems, Packard BioScience, Affymetrix, the 
 Micromass division of Waters, Aurora Biosciences, and Third Wave Technologies. 
The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.